EBMT NEWSLETTER | January 2018 | Volume 60 - Issue 1

EBMT
Important dates

RACE Study

A prospective Randomized multicenter study comparing horse Antithymocyte globuline (hATG) + Cyclosporine A (CsA) with or without Eltrombopag as front-line therapy for severe aplastic anemia patients.

Study design: Open label randomised clinical trial
Phase: III
Primary objective: To investigate whether Eltrombopag added to standard immunosuppressive treatment increases the rate of early (at three months) complete response in untreated aplastic anemia patients.

Status: Janury 9, 2018
 
Countries # Sites # Open # Enrolling # Randomised patients
France 8 7 7 55
Germany 5 0 0 0
Italy 9 4 2 13
Netherlands 4 4 4 18
Spain 4 3 2 4
Switzerland 3 1 1 6
United Kingdom 5 4 3 23
TOTAL 40 23 19 119


RICMAC study and SAA-G-CSF study

Follow up of the Clinical Trials in collaboration with the EBMT Data Office in Leiden.
Bookmark and Share